Acetylator Phenotype and Serum Levels of Sulfapyridine in Patients with Inflammatory Bowel Disease

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1981 Jan 1

PMID 6119205

Citations 3

Authors

M E Sharp

S M Wallace

K W Hindmarsh

M A Brown

Affiliations

Soon will be listed here.

Citing Articles

Genetically determined adverse drug reactions involving metabolism.

Lennard M Drug Saf. 1993; 9(1):60-77.

PMID: 8347292 DOI: 10.2165/00002018-199309010-00006.

Survey of the human acetylator polymorphism in spontaneous disorders.

Evans D J Med Genet. 1984; 21(4):243-53.

PMID: 6387123 PMC: 1049291. DOI: 10.1136/jmg.21.4.243.

Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Clark D Drugs. 1985; 29(4):342-75.

PMID: 2859977 DOI: 10.2165/00003495-198529040-00003.

References

Vree T, OREILLY W, Hekster Y, Damsma J, van der Kleijn E . Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man. Clin Pharmacokinet. 1980; 5(3):274-94. DOI: 10.2165/00003088-198005030-00006. View

Bates T, Blumenthal H, Pieniaszek Jr H . Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine. Clin Pharmacol Ther. 1977; 22(6):917-27. DOI: 10.1002/cpt1977226917. View

Poley J . Chronic inflammatory bowel disease in children and adolescents: part I. South Med J. 1978; 71(8):935-48. DOI: 10.1097/00007611-197808000-00020. View

Fischer C, Klotz U . High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man. J Chromatogr. 1979; 162(2):237-43. DOI: 10.1016/s0378-4347(00)81919-2. View

Day J, Houston J . Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease. Br J Clin Pharmacol. 1980; 9(1):91-4. PMC: 1429913. DOI: 10.1111/j.1365-2125.1980.tb04802.x. View

Das K, Eastwood M, MCMANUS J, Sircus W . The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut. 1973; 14(8):631-41. PMC: 1412758. DOI: 10.1136/gut.14.8.631. View

van Hees P, van Elferen L, van Rossum J, van Tongeren J . Hemolysis during salicylazosulfapyridine therapy. Am J Gastroenterol. 1978; 70(5):501-5. View

Goodacre R, Ali M, Vanderlinden B, Hamilton J, Castelli M, Seaton T . Hemolytic anemia in patients receiving sulfasalazine. Digestion. 1978; 17(6):503-8. DOI: 10.1159/000198156. View

Das K, Eastwood M, MCMANUS J, Sircus W . Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973; 289(10):491-5. DOI: 10.1056/NEJM197309062891001. View

10.

SEREBRO H, Kay S, Javett S, ABRAHAMS C . Sulphasalazine rectal enemas: topical method of inducing remission of active ulcerative colitis affecting rectum and descending colon. Br Med J. 1977; 2(6097):1264. PMC: 1632450. DOI: 10.1136/bmj.2.6097.1264. View

11.

van Hees P, Tuinte J, van Rossum J, van Tongeren J . Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut. 1979; 20(4):300-4. PMC: 1412401. DOI: 10.1136/gut.20.4.300. View

12.

Mucklow J, Bending M, Kahn G, Dollery C . Drug concentration in saliva. Clin Pharmacol Ther. 1978; 24(5):563-70. DOI: 10.1002/cpt1978245563. View

13.

Schroder H, Evans D . Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut. 1972; 13(4):278-84. PMC: 1412167. DOI: 10.1136/gut.13.4.278. View

14.

Poley J . Chronic inflammatory bowel disease in children and adolescents: part II. South Med J. 1978; 71(9):1123-33. DOI: 10.1097/00007611-197809000-00022. View

15.

Das K, Eastwood M . Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease. Clin Pharmacol Ther. 1975; 18(5 Pt 1):514-20. DOI: 10.1002/cpt1975185part1514. View

16.

Goldstein P, Alpers D, Keating J . Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine. J Pediatr. 1979; 95(4):638-40. DOI: 10.1016/s0022-3476(79)80786-6. View

17.

Schroder H, Campbell D . Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972; 13(4):539-51. DOI: 10.1002/cpt1972134539. View

18.

Cowan G, Das K, Eastwood M . Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis. Br Med J. 1977; 2(6094):1057-9. PMC: 1631817. DOI: 10.1136/bmj.2.6094.1057. View

19.

Azad Khan A, Piris J, TRUELOVE S . An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977; 2(8044):892-5. DOI: 10.1016/s0140-6736(77)90831-5. View

20.

Chapron D, Kramer P, Mercik S . Kinetic discrimination of three sulfamethazine acetylation phenotypes. Clin Pharmacol Ther. 1980; 27(1):104-13. DOI: 10.1038/clpt.1980.16. View